Bioasis aims to advance the treatment of CNS diseases by licensing our xB3 platform. We are partnering with biopharmaceutical companies and leading research institutions to conduct research and development activities that will allow us to advance treatments for patients suffering from these devastating diseases and disorders.

Our deep knowledge of the life sciences and pharmaceutical industries has allowed Bioasis to develop strong and meaningful working relationships with many industry leaders. Through collaboration with Bioasis, researchers can conduct experiments with the xB3 platform technology for the delivery and testing of their own compounds.

From the beginning, Bioasis has been at the forefront of innovation. We have collaborated with those dedicated to uncovering new therapies to treat patients suffering from CNS diseases. Bioasis continues to seek strategic relationships with biopharmaceutical partners and research institutions that aim to create and develop treatments for patients suffering from CNS-related diseases and disorders.